Sort   by:  
 Page size 
UnknownPD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Not available
S-EPMC2790859 | biostudies-literature
TranscriptomicsOvarian Tumor Samples: mixed reference of 106 pooled ovarian samples vs. individual patient ovarian sample
The goal of the study was to identify molecular subgroups that might predict clinical outcomes in serous epithelial ovarian cancer (EOC) patients. A second objective was to identify potential therapeutic targets for serous EOC based on improved understanding of the molecular diversity of the diseas...
ORGANISM(S): Homo sapiens 
2013-12-26 | E-GEOD-51088 | biostudies-arrayexpress
UnknownHER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
Not available
S-EPMC5074347 | biostudies-literature
UnknownIdentification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.
Not available
S-EPMC2939826 | biostudies-literature
TranscriptomicsImmune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers [methylation]
Epigenetic therapy is emerging as a potential therapy for solid tumors. To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment with the DNA methyltransferase inhibitor 5-azacitidin...
ORGANISM(S): Homo sapiens 
2014-05-08 | E-GEOD-57342 | biostudies-arrayexpress
TranscriptomicsFOXA1 actively represses the molecular phenotype of basal breast cancers.
Breast cancer is a heterogeneous disease comprised of at least five major subtypes. Luminal subtype tumors confer a more favourable patient prognosis, which is in part, attributed to the Estrogen Receptor-alpha (ER) positivity and anti-hormone responsiveness of these tumors. Expression of the forkhe...
ORGANISM(S): Homo sapiens 
2012-03-09 | E-GEOD-31003 | biostudies-arrayexpress
UnknownPhase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).
Not available
S-EPMC6236634 | biostudies-literature
TranscriptomicsImmune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
ORGANISM(S): Homo sapiens 
2014-05-08 | E-GEOD-57343 | biostudies-arrayexpress
UnknownSpatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.
Not available
S-EPMC8713949 | biostudies-literature
UnknownExpression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.
Not available
S-EPMC3732195 | biostudies-literature
Sort   by:  
 Page size